Acute Kidney Injury (AKI) commonly complicates
|
|
- Roland Stewart
- 5 years ago
- Views:
Transcription
1 IN THE LITERATURE Brain Natriuretic Peptide Therapy to Prevent Acute Kidney Injury After Cardiac Surgery Commentary on Mentzer RM, Oz MC, Sladen RN, et al: Effects of Perioperative Nesiritide in Patients with Left Ventricular Dysfunction undergoing Cardiac Surgery. The NAPA Trial. J Am Coll Cardiol 49: , 2007 Acute Kidney Injury (AKI) commonly complicates the perioperative management of cardiac surgery patients, particularly in patients with preexisting risk factors such as congestive heart failure (CHF) and chronic kidney disease (CKD). It is increasingly recognized that development of AKI following cardiac surgery portends a poor outcome, so that prevention and aggressive management of this complication are important components of perioperative care in high-risk patients. AKI is common following cardiac surgery, occurring in 7.7% (reported in 1 ) to 42% (reported in 2 ) of patients with previously normal renal function, depending on the definition of AKI used. Even small increments in serum creatinine have been shown to be associated with increased mortality after cardiac surgery and other insults. 2-8 There is emerging evidence that any change in serum creatinine may have important prognostic value post cardiac surgery, including increases barely beyond the limits of assay variability. 4 Specifically, postoperative serum creatinine increments of 20% to 25% are associated with mortality increases from the range of 0% to 1% to the range of 12% to 14%, 5,6 and even increments of 0.1 to 0.3 mg/dl (8.84 to mol/l) are associated with significant increased mortality. 4 A variety of patient characteristics (CKD, advanced age, diabetes mellitus, CHF), operative factors (emergent surgery, prolonged cardiopulmonary bypass time, valvular surgery, repeat coronary artery bypass graft surgery), and postoperative events (vasodilatory or cardiogenic shock, bleeding) are known to increase the risk of AKI following cardiac surgery. 1,3,8 Although it is clear that preoperative CKD is the major patient risk factor for severe AKI following cardiac surgery, preoperative CHF is found to be among the other significant risk factors in every cohort study. Furthermore, patients with postoperative lowcardiac output syndrome, vasodilatory shock, 9 and bleeding are highest risk for postoperative AKI. In summary, the adverse prognostic significance of AKI following cardiac surgery is well established, and although prior CKD is the most significant predictor of severe perioperative AKI, preoperative CHF with or without postoperative ventricular dysfunction with cardiogenic shock are among the other significant predictors of adverse renal outcomes. Although preoperative identification of patients at high risk of AKI is possible, there are no proven interventions to prevent AKI following cardiac surgery. 10,11 Careful monitoring of renal function, appropriate use of fluids, vasoactive drugs, and diuretics to optimize renal function, avoidance of nephrotoxins, and appropriate use of renal replacement therapy are regarded as critical approaches to minimize any potential adverse impact of perioperative renal dysfunction on outcomes. However, the current understanding of the pathogenesis of AKI postcardiotomy is incomplete, with evidence supporting multifactorial roles of insults from intraoperative hypoperfusion, nephrotoxin exposure (heme pigments, inflammatory cytokines, oxidant stress, medications), embolism, and ischemia-reperfusion injury, all superimposed on preexisting CKD and CHF-associated renal hypoperfusion in many cases. 11 The use of vasoactive drugs to provide perioperative circulatory support is among the potentially effective options to prevent or ameliorate AKI after cardiac surgery, and of greatest theoretical utility in patients with preoperative CHF with or without postoperative ventricular dysfunction with cardiogenic shock. Address correspondence to Patrick Murray, MD, University of Chicago Hospitals, Section of Nephrology, MC5100, University of Chicago Hospitals, 5841 S Maryland Ave, Chicago, IL pmurray@medicine.bsd.uchicago.edu 2007 by the National Kidney Foundation, Inc /07/ $34.00/0 doi: /j.ajkd American Journal of Kidney Diseases, Vol 51, No 1 (January), 2008: pp 5-9 5
2 6 Patrick Murray Natriuretic peptides are hormones secreted by the heart in response to volume overload with increased cardiac stretch and other stimuli. Atrial natriuretic peptide (ANP) is a 28-amino acid peptide synthesized by atrial myocytes. Brain natriuretic peptide (BNP) is a 32-amino acid peptide synthesized in the brain and in the heart. ANP and BNP are systemic and renal vasodilators that also inhibit renal tubular sodium reabsorption and renin-angiotensin-aldosterone axis activation. The synthetic natriuretic peptide nesiritide (recombinant BNP) is approved for treatment of symptomatic acute decompensated heart failure. In studies in which subjects received unrestricted standard CHF therapy (diuretics, dobutamine), nesiritide therapy lowered pulmonary capillary occlusion pressure and resolved dyspnea more rapidly than nitroglycerin or placebo, 12,13 and the drug was approved for use in acute decompensated heart failure. More recently, meta-analysis of outcome data from these and some other nesiritide CHF trials generated some controversy and an expert panel concluded that further trial data were needed to discern the effects of nesiritide therapy on renal function and survival in patients with acute decompensated heart failure. The panel also reemphasized that the indication for nesiritide therapy is acute decompensated heart failure, not chronic intermittent therapy or other unproven uses. Finally, they noted that the drug should not be used to improve renal function or to augment or replace diuretic therapy in CHF patients, as there is no conclusive proof of the utility of the drug for these purposes, despite some interesting preclinical and pilot studies suggesting that nesiritide could suppress neurohormonal activation and improve diuretic responsiveness in patients with CHF. 17 Uncontrolled studies using nesiritide for cardiovascular support of patients with CHF undergoing cardiac surgery have suggested beneficial effects on renal function Feldman and colleagues administered nesiritide to 10 consecutive patients following cardiac transplantation with oliguric acute-on-chronic renal insufficiency refractory to escalating inotropic support and diuretics, which resulted in decreased pulmonary artery pressures, higher cardiac output, and improved diuretic responsiveness and glomerular filtration rate (GFR). 18 Salzberg and colleagues infused nesiritide to 14 high-risk patients undergoing mitral valve surgery, and found that this therapy acutely lowered pulmonary artery pressures and was associated with much lower perioperative mortality than predicted by risk factor scoring. 19 Beaver and colleagues retrospectively compared 151 patients who received nesiritide within 3 days after cardiothoracic surgery with 789 who did not, to determine effects on the incidence of acute renal failure requiring dialysis or mortality over a 3-year period. 20 They used multiple logistic regression to determine that nesiritide therapy was associated with a significant reduction of the risk of dialysis or death in those with preoperative serum creatinine values greater than 1 mg/dl ( 88.4 mol/l), but not those with lower serum creatinines. Taken together, the findings of these and other studies suggested that a prospective, randomized trial should be performed to test the hypothesis that nesiritide can improve outcomes after cardiac surgery. WHAT DOES THIS IMPORTANT STUDY SHOW? The Nesiritide Administered Peri-Anesthesia in Patients Undergoing Cardiac Surgery (NAPA) trial was a multicenter, randomized, doubleblind, placebo-controlled trial of nesiritide versus placebo in 303 patients with chronic left ventricular dysfunction (ejection fraction 40%) undergoing cardiac surgery (coronary artery bypass graft with or without mitral valve replacement/repair) using cardiopulmonary bypass. 21 Nesiritide was administered as a 24- to 96-hour infusion of 0.01 g/kg/min. The study had multiple exploratory endpoints, aimed to establish drug safety and efficacy in preparation for a larger trial to establish clinical effectiveness. There were 5 primary endpoints, including 3 renal endpoints (change from baseline to peak serum creatinine by the end of hospital stay or day 14; change from baseline estimated GFR [egfr] as measured by the Modification of Diet in Renal Disease [MDRD] Study equation in the same period; urine output during the initial 24 hours of intensive care unit admission), and 2 hemodynamic endpoints (pulmonary artery pressures; other vasoactive drug use). There were no significant differences between the groups in baseline patient characteristics;
3 In the Literature 7 serum creatinine values were approximately 1.1 mg/dl (97 mol/l), with egfr approximately 80 ml/min/1.73 m 2 (1.33 ml/s/1.73 m 2 ). Of 303 randomized patients, 24 did not receive study drug and 7 more were excluded because they had off-pump surgery. The efficacy analysis was restricted to the 272 randomized patients who received study drug and had cardiopulmonary bypass. The safety analysis, including mortality, included all 279 patients who received study drug, irrespective of cardiopulmonary bypass use. The mean duration of study drug infusion was about 40 hours in both groups. Perioperative renal function quantified by the 3 renal primary endpoints was better in the nesiritide group (peak serum creatinine increase of 0.15 mg/dl [13 mol/l] v 0.34 mg/dl [30 mol/l] in the placebo group, P 0.001; egfr decrease of 10.2 ml/min/1.73 m 2 [ 0.17 ml/s/1.73 m 2 ] v 17.8 ml/min/1.73 m 2 [ 0.30 ml/s/1.73 m 2 ]inthe placebo group, P 0.001; initial 24-h urine output L v L in the placebo group, P 0.001). These trends were more pronounced in the small 62-patient subset with preoperative serum creatinine values greater than 1.2 mg/dl ( 106 mol/l). Although serum creatinine increased postoperatively in both groups, it returned to baseline within 12 hours in the nesiritide group, and remained elevated throughout hospitalization in the placebo group. Use of vasoactive drugs and hemodynamic parameters did not differ significantly between the groups. Adverse events also were similar between the groups, as was 30-day and 180-day mortality (although capture of mortality data was incomplete). Among other secondary endpoints, nesiritide was not associated with any change in mechanical ventilation time or intensive care unit length of stay, but hospital length of stay was significantly shorter in the nesiritide group ( days v days in the placebo group; P 0.04). Thus, it appears that administration of nesiritide infusion during and after cardiac surgery with cardiopulmonary bypass in patients with preoperative left ventricular dysfunction has favorable short-term effects on renal function (as measured by serum creatinine changes, calculated GFR, and urine output). This study also showed that short-term adverse effects were comparable to placebo infusion. HOW DOES THIS STUDY COMPARE TO PRIOR STUDIES? More recently, Bail and colleagues demonstrated that intraoperative BNP improved hemodynamics during experimental cardiopulmonary bypass in a porcine model. 22 Furthermore, a small randomized controlled pilot trial in 40 patients with CKD (estimated creatinine clearance 60 ml/min) undergoing cardiopulmonary bypass demonstrated better preservation of renal function (measured by changes in plasma cystatin C and by estimated creatinine clearance) and less perioperative plasma aldosterone increase in the nesiritide group than in the placebo group. 23 Taken together with these newer data and the prior uncontrolled retrospective studies, the results of the NAPA trial suggest potential utility of nesiritide to prevent or ameliorate AKI during cardiac surgery in high-risk patients with CHF and preserved preoperative renal function. Results from similar studies using the related compound ANP also suggest utility of natriuretic peptide therapy for this indication. Specifically, Sezai and colleagues found that perioperative infusion of ANP improved hemodynamics, neurohormonal activation, and urine output during and after coronary artery bypass graft with cardiopulmonary bypass in 3 small prospective trials Similarly, the use of ANP for early therapy of evolving AKI after cardiac surgery resulted in improved renal function in a recent, small, placebo-controlled randomized pilot study. 27 Of course, ANP previously failed to improve dialysis-free survival in a broader group of hospitalized patients with more severe, established acute tubular necrosis in 2 large randomized trials (the latter restricted to oliguric patients), 28,29 and was unsuccessfully tested to prevent radiocontrast nephropathy 30 or improve the course of delayed graft function following cadaveric renal transplantation. 31,32 WHAT SHOULD CLINICIANS AND RESEARCHERS DO? Although it appears that administration of nesiritide infusion during and after cardiac surgery with cardiopulmonary bypass in patients with preoperative left ventricular dysfunction has favorable shortterm effects on renal function, the prespecified renal endpoints were physiologic measures of drug efficacy, not clinical effectiveness. 33 Serum creatinine changes, calculated GFR, and urine output are
4 8 not proven surrogates; despite their common use as primary endpoints in AKI trials, none of these efficacy measures has been validated to reliably predict the effectiveness of interventions to improve clinical outcomes in prospective trials. 33,34 Until the prophylactic use of nesiritide is proven to improve clinical outcomes after cardiac surgery, such as dialysis-free survival, this should not be accepted as an indication for use of this drug. Although there is a wealth of data associating AKI defined by small increments in serum creatinine with adverse outcomes, no therapy that prevents such creatinine increases has also been shown to improve hard clinical outcomes (dialysis indication/ initiation, survival, dialysis-free survival). The lack of validation of such a surrogate (or others, such as AKI resulting in sustained GFR loss with new or worsening CKD) remains a major obstacle to drug development for AKI prevention and therapy. This study also fails to demonstrate a convincing mechanism of the observed beneficial effects on renal function. It is interesting to speculate that, based upon these results, any renoprotective effect of this vasoactive drug during and after cardiopulmonary bypass is not mediated by effects on systemic perfusion (which was similar in both groups), rather suggesting an effect on regional perfusion, or a pleiotropic phenomenon. However, it should be noted that although a similar proportion of each group received vasoactive drugs, the doses prescribed and an integrated picture of the level of vasoactive drug support required to maintain similar hemodynamic profiles in both groups is not provided in this paper. It is conceivable that occult effects of varying drug and dose combinations on regional perfusion played a role in the results of the study. Finally, the design of the trial was appropriate for phase 2 drug development, including multiple exploratory primary endpoints, and not intended to support any claim of a new indication for the use of nesiritide. The interesting findings of this study provide a strong rationale for a definitive clinical trial to prove utility of nesiritide for renoprotection during cardiac surgery in patients with left ventricular dysfunction. Patrick Murray, MD University of Chicago Hospitals Chicago, Illinois Patrick Murray ACKNOWLEDGEMENTS Support: None. Financial Disclosure: Dr Murray reports having received speaking fees from Scios Inc (the manufacturer of nesiritide) in 2005 and having served as a paid consultant for the company in REFERENCES 1. Mangano CM, Diamondstone LS, Ramsey JG, et al: Renal dysfunction after myocardial revascularization: Risk factors, adverse outcomes, and hospital resource utilization. Ann Intern Med 128: , Tuttle KR, Worrall NK, Dahlstrom LR, et al: Predictors of ARF after cardiac surgical procedures. Am J Kidney Dis 41:76-83, Chertow GM, Lazarus JM, Christiansen CL, et al: Preoperative renal risk stratification. Circulation 95: , Lassnigg AL, Schmidlin D, Mouhieddine M, et al: Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: A prospective cohort study. J Am Soc Nephrol 15: , Ryckwaert F, Boccara G, Frappier J-M, et al: Incidence, risk factors, and prognosis of a moderate increase in plasma creatinine after cardiac surgery. Crit Care Med 30: , Loef BG, Epema AH, Smilde TD, et al: Immediate postoperative renal function deterioration in cardiac surgical patients predicts in-hospital mortality and survival. J Am Soc Nephrol 16: , Leacche M, Rawn JD, Mihalijevic T, et al: Outcomes in patients with normal serum creatinine and with artificial renal support for acute renal failure developing after coronary artery bypass grafting. Am J Cardiol 93: , Conlon PJ, Stafford-Smith M, White WD, et al: Acute renal failure following cardiac surgery. Neph Dial Transplant 14: , Ruel M, Khan TA, Voisine P, et al: Vasomotor dysfunction after cardiac surgery. Eur J Cardiothorac Surg 26: , Tang I, Murray PT: Prevention of perioperative ARF: What works? Best Pract Res ClinAnaesthesiol 18:91-111, Rosner MH, Okusa MD: Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol 1:19-32, Colucci WS, Elkayam U, Horton DP, et al: Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 343: , Publication Committee for the VMAC Investigators: Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287: , Sackner-Bernstein JD, Kowalski M, Fox M, et al: Short-term risk of death after treatment with nesiritide for decompensated heart failure. A pooled analysis of randomized controlled trials. JAMA 293: , Sackner-Bernstein JD, Skopicki HA, Aaronson KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111: , 2005
5 In the Literature Topol EJ: Nesiritide not verified. N Engl J Med 353: , Cataliotti A, Boerrigter G, Costello-Boerrigter LC, et al: Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation 109: , Feldman DS, Ikonomidis JS, Uber WE, et al: Human B-natriuretic peptide improves hemodynamics and renal function in heart transplant patients immediately after surgery. J Card Fail 10: , Salzberg SP, Filsoufi F, Anyanwu A, et al: High-risk mitral valve surgery: perioperative hemodynamic optimization with nesiritide (BNP). Ann Thorac Surg 80: , Beaver TM, Winterstein AG, Shuster JJ, et al: Effectiveness of nesiritide on dialysis or all-cause mortality in patients undergoing cardiothoracic surgery. Clin Cardiol 29:18-24, Mentzer RM, Oz MC, Sladen RN, et al: Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery. The NAPA Trial. J Am Coll Cardiol 49: , Bail DHL, Steger V, Heinzelmann U, et al: Administration of brain natriuretic peptide improves cardiac function following operations using extracorporeal circulation in an animal model. Clin Sci 112: , Chen HH, Sundt TM, Cook DJ, et al: Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot. Circulation 116: , 2007 (suppl 11) 24. Sezai A, Shiono M, Orime Y, et al: Low-dose continuous infusion of human atrial natriuretic peptide during and after cardiac surgery. Ann Thorac Surg 69: , Sezai A, Hata M, Wakui S, et al: Efficacy of low-dose continuous infusion of human atrial natriuretic peptide (hanp) during cardiac surgery. Possibility of postoperative left ventricular remodeling effect. Circ J 70: , Sezai A, Hata M, Wakui S, et al: Efficacy of continuous low-dose hanp administration in patients undergoing emergent coronary artery bypass grafting for acute coronary syndrome. Circ J 71: , Sward K, Valsson F, Odencrants P, et al: Recombinant human atrial natriuretic peptide in ischemic acute renal failure. A randomized placebo controlled trial. Crit Care Med 32: , Allgren RL, Marbury TC, Rahman SN, et al: Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med 336: , Lewis J, Salm MM, Chertow GM, et al: Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney Dis 36: , Sands JM, Neylan JF, Olson RA, et al: Atrial natriuretic factor does not improve the outcome of cadaveric renal transplantation. J Am Soc Nephrol 1: , Ratcliffe PJ, Richardson AJ, Kirby JE, et al: Effect of intravenous infusion of atriopeptin 3 on immediate renal allograft function. Kidney Int 39: , Kurnik BR, Allgren RL, Genter FC, et al: Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kid Dis 31: , Murray PT, Le Gall JR, Dos Reis Miranda D, et al: Physiologic endpoints (efficacy) for acute renal failure studies. Curr Opin Crit Care 8: , Palevsky PM, Metnitz PG, Piccinni P, et al: Selection of endpoints for clinical trials of acute renal failure in critically ill patients. Curr Opin Crit Care 8: , 2002
Projecting the Effect of Nesiritide on Dialysis and Hospital Mortality in Cardiac Surgery Patientsvhe_
Volume 13 Number 5 2010 VALUE IN HEALTH Projecting the Effect of Nesiritide on Dialysis and Hospital Mortality in Cardiac Surgery Patientsvhe_710 643..648 Jinghua He, MS, Almut G. Winterstein, PhD, Thomas
More informationEffects of Perioperative Nesiritide in Patients With Left Ventricular Dysfunction Undergoing Cardiac Surgery
Journal of the American College of Cardiology Vol. 49, No. 6, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.10.048
More informationPreoperative Serum Bicarbonate Levels Predict Acute Kidney Iinjry after Cardiac Surgery
International Journal of ChemTech Research CODEN (USA): IJCRGG, ISSN: 0974-4290, ISSN(Online):2455-9555 Vol.11 No.06, pp 203-208, 2018 Preoperative Serum Bicarbonate Levels Predict Acute Kidney Iinjry
More informationJournal of the American College of Cardiology Vol. 58, No. 9, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 58, No. 9, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.03.056
More informationHeart Failure. Nesiritide Does Not Improve Renal Function in Patients With Chronic Heart Failure and Worsening Serum Creatinine
Heart Failure Nesiritide Does Not Improve Renal Function in Patients With Chronic Heart Failure and Worsening Serum Creatinine David J. Wang, MD; Thomas C. Dowling, PhD; Dean Meadows, MD; Tomas Ayala,
More informationJournal of the American College of Cardiology Vol. 55, No. 17, by the American College of Cardiology Foundation ISSN /10/$36.
Journal of the American College of Cardiology Vol. 55, No. 17, 21 21 by the American College of Cardiology Foundation ISSN 735-197/1/$36. Published by Elsevier Inc. doi:1.116/j.jacc.29.11.85 CLINICAL TRIALS
More informationMedical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine
Medical Management of Acutely Decompensated Heart Failure William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Goals of Acute Heart Failure Therapy Alleviate
More informationNesiritide: Harmful or Harmless?
Nesiritide: Harmful or Harmless? Michael P. Dorsch, Pharm.D., and Jo Ellen Rodgers, Pharm.D. Nesiritide is the recombinant form of human B-type (brain) natriuretic peptide (BNP), and its amino acid sequence
More informationPivotal Role of Renal Function in Acute Heart failure
Pivotal Role of Renal Function in Acute Heart failure Doron Aronson MD, FESC Department of Cardiology RAMBAM Health Care Campus Haifa, Israel Classification and definitions of cardiorenal syndromes CRS
More informationContrast Induced Nephropathy
Contrast Induced Nephropathy O CIAKI refers to an abrupt deterioration in renal function associated with the administration of iodinated contrast media O CIAKI is characterized by an acute (within 48 hours)
More informationAcute kidney injury prediction following elective cardiac surgery: AKICS Score
original article http://www.kidney-international.org & 2007 International Society of Nephrology Acute kidney injury prediction following elective cardiac surgery: AKICS Score H Palomba 1, I de Castro 1,
More informationUniversity of Groningen. Acute kidney injury after cardiac surgery Loef, Berthus Gerard
University of Groningen Acute kidney injury after cardiac surgery Loef, Berthus Gerard IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it.
More informationOriginal Article. Jose Iglesias 1,2, Deborah Hom 2, Maria Antoniotti 2, Sammy Ayoub 2 and Jerrold S. Levine 3. Introduction
Nephrol Dial Transplant (2006) 21: 3458 3465 doi:10.1093/ndt/gfl428 Advance Access publication 28 July 2006 Original Article Predictors of worsening renal function in adult patients with congestive heart
More informationAcute Kidney Injury for the General Surgeon
Acute Kidney Injury for the General Surgeon UCSF Postgraduate Course in General Surgery Maui, HI March 20, 2011 Epidemiology & Definition Pathophysiology Clinical Studies Management Summary Hobart W. Harris,
More informationInfluence of Continuous Infusion of Low-Dose Human Atrial Natriuretic Peptide on Renal Function During Cardiac Surgery
Journal of the American College of Cardiology Vol. 54, No. 12, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.05.047
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationThe Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?
The Who, How and When of Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center Lebanon, NH May 20, 2013 Joseph G. Rogers,
More informationWORSENING OF RENAL FUNCTION AFTER RAS INHIBITION IN DECOMPENSATED HEART FAILURE: CLINICAL IMPLICATIONS
WORSENING OF RENAL FUNCTION AFTER RAS INHIBITION IN DECOMPENSATED HEART FAILURE: CLINICAL IMPLICATIONS George Bakris, MD, FASH, FAHA, FASN Professor of Medicine Director, Comprehensive Hypertension Center
More informationThe Cardiorenal Syndrome in Heart Failure
The Cardiorenal Syndrome in Heart Failure Van N Selby, MD Assistant Professor of Medicine Advanced Heart Failure Program, UCSF October 9, 2015 Disclosures None 1 Cardiorenal Syndrome (CRS) A pathophysiologic
More informationTHE KIDNEY IN HYPOTENSIVE STATES. Benita S. Padilla, M.D.
THE KIDNEY IN HYPOTENSIVE STATES Benita S. Padilla, M.D. Objectives To discuss what happens when the kidney encounters low perfusion To discuss new developments and clinical application points in two scenarios
More informationPrediction of acute renal failure after cardiac surgery: retrospective cross-validation of a clinical algorithm
Nephrol Dial Transplant (2003) 18: 77 81 Original Article Prediction of acute renal failure after cardiac surgery: retrospective cross-validation of a clinical algorithm Bjørn O. Eriksen 1, Kristel R.
More informationManagement of Acute Heart Failure
Management of Acute Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu ADHF Treatments Goals.2 Improve symptoms.
More informationHeart Failure and Renal Disease Cardiorenal Syndrome
Advanced Heart Failure: Clinical Challenges Heart Failure and Renal Disease Cardiorenal Syndrome 17 th Apr 2015 Ju-Hee Lee, M.D Cardiovascular Center, Chungbuk National University Hospital Chungbuk National
More informationWHY ADMINISTER CARDIOTONIC AGENTS?
Cardiac Pharmacology: Ideas For Advancing Your Clinical Practice The image cannot be displayed. Your computer may not have enough memory to open the image, or Roberta L. Hines, M.D. Nicholas M. Greene
More informationCardiorenal Syndrome: What the Clinician Needs to Know. William T. Abraham, MD Director, Division of Cardiovascular Medicine
Cardiorenal Syndrome: What the Clinician Needs to Know William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Renal Hemodynamics in Heart Failure Glomerular
More informationDoppler ultrasound, see Ultrasonography. Magnetic resonance imaging (MRI), kidney oxygenation assessment 75
Subject Index Acidemia, cardiorenal syndrome type 3 146 Acute Dialysis Quality Initiative (ADQI) acute kidney injury biomarkers, see Acute kidney injury; specific biomarkers cardiorenal syndrome, see specific
More informationTHE ROLE OF NESIRITIDE IN THE MANAGEMENT OF ACUTE DECOMPENSATED HEART FAILURE: REVIEW OF MORTALITY DATA AND RECOMMENDATIONS FOR CLINICAL USE
THE ROLE OF NESIRITIDE IN THE MANAGEMENT OF ACUTE DECOMPENSATED HEART FAILURE: REVIEW OF MORTALITY DATA AND RECOMMENDATIONS FOR CLINICAL USE J. Douglas Kirk MD, FACEP Department of Emergency Medicine,
More informationPrevention of Acute Renal Failure Role of vasoactive drugs and diuretic agents
of Acute Renal Failure Role of vasoactive drugs and diuretic agents Armand R.J. Girbes Prof.dr. A.R.J. Girbes Chairman department of Intensive Care VU University Medical Center Netherlands (Failure of)
More informationCardiorenal Syndrome
SOCIEDAD ARGENTINA DE CARDIOLOGIA Cardiorenal Syndrome Joint session ESC-SAC ESC Congress 2012, Munich César A. Belziti Hospital Italiano de Buenos Aires I have no conflicts of interest to declare Cardiorenal
More informationNesiritide: new hope for acute heart failure syndromes?
European Heart Journal Supplements (2005) 7 (Supplement B), B25 B30 doi:10.1093/eurheartj/sui010 Nesiritide: new hope for acute heart failure syndromes? John C. Burnett* Department of Medicine, Mayo Clinic
More informationHyponatremia in Heart Failure: why it is important and what should we do about it?
Objectives Hyponatremia in Heart Failure: why it is important and what should we do about it? Pathophysiology of sodium and water retention in heart failure Hyponatremia in heart failure (mechanism and
More informationUpdate on Cardiorenal Syndrome: A Clinical Conundrum
Advances in Peritoneal Dialysis, Vol. 27, 2011 Eric J. Chan, 1 Kevin C. Dellsperger 1 3 Update on Cardiorenal Syndrome: A Clinical Conundrum Our understanding of the cardiorenal syndrome continues to progress.
More informationWhat s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine
What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine Current Guideline of Treatment Asymptomatic Mild/Mod Severe Refractory Correct Cause: Arrhythmias
More informationCORONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP OVERVIEW
CONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP OVERVIEW 2015 PQRS OPTIONS F MEASURES GROUPS: 2015 PQRS MEASURES IN CONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP: #43 Coronary Artery Bypass Graft (CABG):
More informationCARDIAC SURGERY is viewed as one of the great medical
Association Between Postoperative Acute Kidney Injury and Duration of Cardiopulmonary Bypass: A Meta-Analysis Avinash B. Kumar, MD, FCCP,* Manish Suneja, MD, Emine O. Bayman, PhD,* Garry D. Weide, DO,*
More information16/05/2018 NEFROPATIA DA MEZZO DI CONTRASTO: ANCORA UNA VECCHIA NEMICA?
16/05/2018 NEFROPATIA DA MEZZO DI CONTRASTO: ANCORA UNA VECCHIA NEMICA? Dott. Andrea Boccatonda Università degli Studi G. d Annunzio Chieti Chi di voi non ha mai discusso con un radiologo per eseguire
More informationOriginal Article. Jose I. Iglesias 1 5, Laura DePalma 6, Deborah Hom 3 5, Maria Antoniotti 3 5, Sammy Ayoub 3 5 and Jerrold S. Levine 7.
Nephrol Dial Transplant (2008) 23: 144 153 doi:10.1093/ndt/gfm565 Advance Access publication 5 September 2007 Original Article Predictors of mortality in adult patients with congestive heart failure receiving
More informationAllinaHealthSystem 1
: Definition End-organ hypoperfusion secondary to cardiac failure Venoarterial ECMO: Patient Selection Michael A. Samara, MD FACC Advanced Heart Failure, Cardiac Transplant & Mechanical Circulatory Support
More informationHeart Failure and Renal Failure. Gerasimos Filippatos, MD, FESC, FHFA President HFA
Heart Failure and Renal Failure Gerasimos Filippatos, MD, FESC, FHFA President HFA Definition Epidemiology Pathophysiology Management (?) Recommendations for NHLBI in cardiorenal interactions related to
More informationCardiorenal Syndrome
Cardiorenal Syndrome Peenida Skulratanasak, M.D. Division of Nephrology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University Definition of Cardiorenal syndrome (CRS) Structural
More informationHeart Failure and Cardio-Renal Syndrome 1: Pathophysiology. Biomarkers of Renal Injury and Dysfunction
CRRT 2011 San Diego, CA 22-25 February 2011 Heart Failure and Cardio-Renal Syndrome 1: Pathophysiology Biomarkers of Renal Injury and Dysfunction Dinna Cruz, M.D., M.P.H. Department of Nephrology San Bortolo
More informationClinical efficacy of ultrafiltration in the treatment of acute decompensated heart failure with diuretic resistance.
Biomedical Research 2017; 28 (14): 6155-6159 ISSN 0970-938X www.biomedres.info Clinical efficacy of ultrafiltration in the of acute decompensated heart failure with diuretic resistance. Jian Zhang, Qi
More informationAcute Kidney Injury after Cardiac Surgery: Incidence, Risk Factors and Prevention
Acute Kidney Injury after Cardiac Surgery: Incidence, Risk Factors and Prevention Hong Liu, MD Professor of Clinical Anesthesiology Department of Anesthesiology and Pain Medicine University of California
More informationRisk Factors and Management of Acute Renal Injury in Cardiac Surgery
Risk Factors and Management of Acute Renal Injury in Cardiac Surgery Robert S Kramer, MD, FACS Clinical Associate Professor of Surgery Tufts University School of Medicine Maine Medical Center, Portland
More informationCardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology
Cardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology Heart and Kidney The kidney yin dominates water, The heart yang
More informationFluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI)
Fluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI) Robert W. Schrier, MD University of Colorado School of Medicine Denver, Colorado USA Prevalence of acute renal failure in Intensive
More informationTopic Page: congestive heart failure
Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation
More informationPaul M McKie, Alessandro Cataliotti, Guido Boerrigter, Horng C Chen, Fernando L Martin, and John C Burnett Jr
Cardiorenal Enhancing and Aldosterone Suppressing Actions of a Novel Designer Natriuretic Peptide in Experimental Hypertension with Ventricular Pressure Overload Paul M McKie, Alessandro Cataliotti, Guido
More informationchanging the diagnosis and management of acute kidney injury
changing the diagnosis and management of acute kidney injury NGAL NGAL is a novel biomarker for diagnosing acute kidney injury (AKI). The key advantage of NGAL is that it responds earlier than other renal
More informationThe Treatment Targets in Acute Decompensated Heart Failure
SUCCESS WITH HEART FAILURE The Treatment Targets in Acute Decompensated Heart Failure Gregg C. Fonarow, MD The Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, UCLA School of Medicine, Los
More informationDr.Nahid Osman Ahmed 1
1 ILOS By the end of the lecture you should be able to Identify : Functions of the kidney and nephrons Signs and symptoms of AKI Risk factors to AKI Treatment alternatives 2 Acute kidney injury (AKI),
More informationTAVR in patients with. End-Stage CKD or in Renal Replacement Therapy:
TAVR in patients with End-Stage CKD or in Renal Replacement Therapy: Special Considerations and Prevention of early Valve Failure Antonios Chalapas, MD, PhD, FESC THV & Hygeia Hospital Heart Team Athens,
More informationPROTECTING THE KIDNEYS FROM PERIOPERATIVE ISCHEMIA. Connie Lynne Lorette, PhD, CRNA Northeastern University Boston MA
PROTECTING THE KIDNEYS FROM PERIOPERATIVE ISCHEMIA Connie Lynne Lorette, PhD, CRNA Northeastern University Boston MA Key Points Pathophysiology and diagnostic criteria for perioperative renal failure Risk
More informationRenal Protective Effects and the Prevention of Contrast-Induced Nephropathy by Atrial Natriuretic Peptide
Journal of the American College of Cardiology Vol. 53, No. 12, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.10.061
More informationLnformation Coverage Guidance
Lnformation Coverage Guidance Coverage Indications, Limitations, and/or Medical Necessity Abstract: B-type natriuretic peptide (BNP) is a cardiac neurohormone produced mainly in the left ventricle. It
More informationKeynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes?
Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor
More informationOvercoming the Cardiorenal Syndrome
Overcoming the Cardiorenal Syndrome October 29, 2016 Randall C Starling MD MPH FACC FESC FHFSA FHFA Professor of Medicine Heart & Vascular Institute Cleveland Clinic Lerner College of Medicine Cleveland
More informationENDPOINTS FOR AKI STUDIES
ENDPOINTS FOR AKI STUDIES Raymond Vanholder, University Hospital, Ghent, Belgium SUMMARY! AKI as an endpoint! Endpoints for studies in AKI 2 AKI AS AN ENDPOINT BEFORE RIFLE THE LIST OF DEFINITIONS WAS
More informationPrevalence of anemia and cardiovascular diseases in chronic kidney disease patients: a single tertiary care centre study
International Journal of Advances in Medicine Sathyan S et al. Int J Adv Med. 2017 Feb;4(1):247-251 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20170120
More informationCardio-Renal Syndrome in Acute Heart Failure:
Cardio-Renal Syndrome in Acute Heart Failure: Target for Therapy Marvin A. Konstam, M.D. Research support and/or consulting relevant to this lecture: Merck, Otsuka, Johnson & Johnson; Amgen; Cardiokine
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationThe development of cardiogenic shock portends an extremely poor prognosis. Cardiogenic Shock: A Lethal Complication of Acute Myocardial Infarction
TREATMENT UPDATE Cardiogenic Shock: A Lethal Complication of Acute Myocardial Infarction David R. Holmes, Jr, MD Mayo Graduate School of Medicine, Mayo Clinic, Rochester, MN Cardiogenic shock is a serious
More informationComparison and clinical suitability of eight prediction models for cardiac surgery-related acute kidney injury
Nephrol Dial Transplant (2013) 28: 345 351 doi: 10.1093/ndt/gfs518 Advance Access publication 4 December 2012 Comparison and clinical suitability of eight prediction models for cardiac surgery-related
More informationPaul R. Bowlin, M.D. University of Colorado Denver. May 12 th, 2008
Paul R. Bowlin, M.D. University of Colorado Denver May 12 th, 2008 Presentation Overview Background / Definitions History Indications for initiation of therapy Outcomes Studies Conclusions Questions Background
More informationAdvanced Care for Decompensated Heart Failure
Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
More informationBiomarkers for optimal management of heart failure. Cardiorenal syndrome. Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland
Biomarkers for optimal management of heart failure Cardiorenal syndrome Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland Presenter Disclosure Information V-P Harjola The following
More informationIntravenous Inotropic Support an Overview
Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)
More informationOverview & Update on the Utilization of the Natriuretic Peptides in Heart Failure
June 28, 2016 Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure Linda C. Rogers, PhD, DABCC, FACB. Agenda Overview of the Natriuretic Peptides and Efficacy studies Similarities
More informationIntraoperative application of Cytosorb in cardiac surgery
Intraoperative application of Cytosorb in cardiac surgery Dr. Carolyn Weber Heart Center of the University of Cologne Dept. of Cardiothoracic Surgery Cologne, Germany SIRS & Cardiopulmonary Bypass (CPB)
More informationHyponatremia as a Cardiovascular Biomarker
Hyponatremia as a Cardiovascular Biomarker Uri Elkayam, MD Professor of Medicine University of Southern California Keck School of Medicine elkayam@usc.edu Disclosure Research grant from Otsuka for the
More informationJMSCR Vol 06 Issue 12 Page December 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i12.02 Original Research Article Fractional
More informationPearls in Acute Heart Failure Management
Pearls in Acute Heart Failure Management Best Practices Juan M. Aranda Jr., M.D. Professor of Medicine Medical Director of Heart Failure/ Transplant Program University of Florida College of Medicine Disclosures:
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal. Serelaxin for treating acute decompensation of heart failure
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Serelaxin for treating acute decompensation of heart Draft scope (pre-referral) Draft remit/appraisal objective To
More informationObjectives 6/14/2016. Cardiorenal Syndrome: Critical Link Between Heart and Kidney
Cardiorenal Syndrome: Critical Link Between Heart and Kidney Chris M. Bell, ACNP Cardiology Associates of North Mississippi Objectives Review the 5 Subtypes of the Cardiorenal Syndrome (CRS) Discuss the
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationMonitoring of Renal Function in Heart Failure
Monitoring of Renal Function in Heart Failure Adriaan A. Voors, cardiologist The Netherlands Disclosures AAV received consultancy fees and/or research grants from: Alere, Bayer, Cardio3Biosciences, Celladon,
More informationRamani GV et al. Mayo Clin Proc 2010;85:180-95
THERAPIES FOR ADVANCED HEART FAILURE: WHEN TO REFER Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation
More informationAvailable online at Vol. 10, Issue, 09, pp , September, DOI:
z ISSN: 0975-833X Available online at http://www.journalcra.com International Journal of Current Research Vol. 10, Issue, 09, pp.73768-73781, September, 2018 DOI: https://doi.org/10.24941/ijcr.32236.09.2018
More informationProtocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year
PAST MEDICAL HISTORY Has the subject had a prior episode of heart failure? o Does the subject have a prior history of exposure to cardiotoxins, such as anthracyclines? URGENT HEART FAILURE VISIT Did heart
More informationHow to manage ACS patients with Comorbidities? Patients with Renal Failure
How to manage ACS patients with Comorbidities? Patients with Renal Failure François Schiele, MD, PhD Department of Cardiology, University Hospital Jean Minjoz, Besançon, France. Potential conflicts of
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationInnovation therapy in Heart Failure
Innovation therapy in Heart Failure P. Laothavorn September 2015 Topics of discussion Basic Knowledge about heart failure Standard therapy New emerging therapy References: standard Therapy in Heart Failure
More informationSummary Protocol ISRCTN / NCT REVIVED-BCIS2 Summary protocol version 4, May 2015 Page 1 of 6
Summary Protocol REVIVED-BCIS2 Summary protocol version 4, May 2015 Page 1 of 6 Background: Epidemiology In 2002, it was estimated that approximately 900,000 individuals in the United Kingdom had a diagnosis
More informationCardiogenic Shock. Carlos Cafri,, MD
Cardiogenic Shock Carlos Cafri,, MD SHOCK= Inadequate Tissue Mechanisms: Perfusion Inadequate oxygen delivery Release of inflammatory mediators Further microvascular changes, compromised blood flow and
More informationManagement of Advanced Systolic Heart Failure. Robert W. Hull MD FACC Associate Professor of Medicine West Virginia University
Management of Advanced Systolic Heart Failure Robert W. Hull MD FACC Associate Professor of Medicine West Virginia University American College of Cardiology Foundation (ACCF) American Heart Association
More informationΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ. ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ Ά ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Διευθυντής: Καθηγητής Δημήτριος Τούσουλης ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
More informationProduct: Omecamtiv Mecarbil Clinical Study Report: Date: 02 April 2014 Page 1
Date: 02 April 2014 Page 1. 2. SYNOPSIS Name of Sponsor: Amgen Inc. Name of Finished Product: Omecamtiv mecarbil injection Name of Active Ingredient: Omecamtiv mecarbil (AMG 423) Title of Study: A double-blind,
More informationOPCAB IS NOT BETTER THAN CONVENTIONAL CABG
OPCAB IS NOT BETTER THAN CONVENTIONAL CABG Harold L. Lazar, M.D. Harold L. Lazar, M.D. Professor of Cardiothoracic Surgery Boston Medical Center and the Boston University School of Medicine Boston, MA
More informationEfficacy and safety of nesiritide in patients with decompensated heart failure: a meta-analysis of randomised trials
To cite: Gong B, Wu Z, Li Z. Efficacy and safety of nesiritide in patients with : a meta-analysis of randomised trials. BMJ Open 2016;6:e008545. doi:10.1136/bmjopen-2015-008545 Prepublication history for
More informationNesiritide is a potent vasodilator proven to rapidly reduce
Heart Failure Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure Jonathan D. Sackner-Bernstein, MD; Hal A. Skopicki, MD, PhD; Keith D. Aaronson, MD, MS
More informationCoronary Artery Bypass Graft: Monitoring Patients and Detecting Complications
Coronary Artery Bypass Graft: Monitoring Patients and Detecting Complications Madhav Swaminathan, MD, FASE Professor of Anesthesiology Division of Cardiothoracic Anesthesia & Critical Care Duke University
More informationState of the Art: acute heart failure Is it just congestion?
ESC CONGRESS 2017 Barcelona, 26. 30. August 2017 State of the Art: acute heart failure Is it just congestion? S.B. Felix, FESC Klinik für Innere Medizin B Ernst-Moritz-Arndt-Universität Greifswald 1456
More informationMedical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011
Medical Treatment for acute Decompensated Heart Failure Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011 2010 HFSA guidelines for ADHF 2009 focused update of the 2005 American College
More informationTreating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment
ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University
More informationIschemic Mitral Valve Disease: Repair, Replace or Ignore?
Ischemic Mitral Valve Disease: Repair, Replace or Ignore? Fabio B. Jatene Full Professor of Cardiovascular Surgery, Medical School, University of São Paulo, Brazil DISCLOSURE I have no financial relationship
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More informationContrast-Induced Nephropathy: Evidenced Based Prevention
Contrast-Induced Nephropathy: Evidenced Based Prevention Michael J Cowley, MD, FSCAI Nothing to disclose Contrast-Induced Nephropathy (CIN) Definitions New onset or worsening of renal function after contrast
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationRenal effects of ularitide in patients with decompensated heart failure
Renal effects of ularitide in patients with decompensated heart failure Hartmut Lüss, MD, a,b Veselin Mitrovic, MD, c Petar M. Seferovic, MD, d Dejan Simeunovic, MD, d Arsen D. Ristić, MD, d Valentin S.
More information